Subsequently, the development of LILRB4 specific nanobody-based Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) cells have demonstrated cytotoxic activity against LILRB4 + AML cell lines in vitro and corresponding anti-leukemic activity in vivo [86]. The gene discussed is LILRB4; the disease is acute myeloid leukemia.